Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Mar 26, 2021 11:32am
196 Views
Post# 32886212

News Financial Interview with Elsley

News Financial Interview with ElsleyInterview today with Elsley.

The interview covers a number of areas.

To me what's most exciting is the pending NASDAQ listing, what's most disappointing is the update on Cortalex sales and how they will do a marketing ramp up later this year. Really the product has been for sale now for 5+ months and you will focus on it later this year, that's like a 12 month ramp up, very disappointing for current shareholders.

To me it's reads that they are so focused on Covid and AM trials that Cortalex is almost an afterthought.

Still, I'm long on CRDL, they will be a Billion Dollar company, so I see their shares trading between $30-50 within the next year.

Enjoy the read....

https://news.financial/interviews/interview-with-cardiol-therapeutics-how-the-heart-disease-specialist-company-plans-to-take-off-on-the-nasdaq-in-2021
<< Previous
Bullboard Posts
Next >>